Conversely, in cancer, where immune responses are often suppressed, simultaneous blockade of both pathways may enhance antitumor immunity by suppressing inhibitory BTLA-mediated signaling and by disrupting pro-tumor HVEM-mediated signaling within the tumor microenvironment.,, Thus, peptide A5 represents a promising dual-targeting molecule with potential applications in both autoimmunity and oncology. Here, BTLA is linked to cancer.